TCR Redirected T Cells for Cancer Treatment: Achievements, Hurdles, and Goals-Reference-Cited by-同舟云学术

TCR Redirected T Cells for Cancer Treatment: Achievements, Hurdles, and Goals

Published:2020-09-03 Issue: Volume:11 Page:
ISSN:1664-3224
Container-title:Frontiers in Immunology
language:
Short-container-title:Front. Immunol.

Author:

Manfredi Francesco,Cianciotti Beatrice Claudia,Potenza Alessia,Tassi Elena,Noviello Maddalena,Biondi Andrea,Ciceri Fabio,Bonini Chiara,Ruggiero Eliana

Funder

Associazione Italiana per la Ricerca sul Cancro

Ministero della Salute

Ministero dell’Istruzione, dell’Università e della Ricerca

Cancer Research UK

Fundación Científica Asociación Española Contra el Cáncer

Publisher

Frontiers Media SA

Subject

Immunology,Immunology and Allergy

Reference393 articles.

1. T cell–inflamed versus Non-T cell–inflamed tumors: a conceptual framework for cancer immunotherapy drug development and combination therapy selection;Trujillo;Cancer Immunol Res.,2018

2. Graft-versus-leukemia reactions after bone marrow transplantation;Horowitz;Blood.,1990

3. Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study;Topalian;J Clin Oncol.,1988

4. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19;Kochenderfer;Blood.,2010

5. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia;Porter;N Engl J Med.,2011

Cited by 74 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Regulatory T cell-based therapy in type 1 diabetes: Latest breakthroughs and evidence;International Immunopharmacology;2024-10

2. Engineered T cells for Colorectal Cancer;Immunotherapy;2024-09-04

3. Expanding horizons in cancer therapy by immunoconjugates targeting tumor microenvironments;Critical Reviews in Oncology/Hematology;2024-09

4. Assessing a single-cell multi-omic analytic platform to characterize ex vivo-engineered T-cell therapy products;Frontiers in Bioengineering and Biotechnology;2024-08-20

5. Harnessing the tumor microenvironment to boost adoptive T cell therapy with engineered lymphocytes for solid tumors;Seminars in Immunopathology;2024-07-25